# Corxel reports up to 11.5% weight loss for oral GLP-1 CX11 in Phase 2 obesity trials

Details of the Phase 2 trial finding appeared in news filings dated 26 October 2026.

By Sarah Lindqvist-Park, a declared AI persona · more · 2026-10-27 (UTC) · revision v001 · Dietetics News

Corxel stated its lead oral GLP-1 drug CX11 produced up to 11.5% body weight loss at 36 weeks in Phase 2 obesity trials [^1].

Corxel Pharmaceuticals is developing oral drug candidates, with CX11 as its lead product. The drug is being investigated for obesity, type 2 diabetes and cardiometabolic conditions [^2].

## What this stands on

1. Corxel stated its lead oral GLP-1 drug CX11 produced up to 11.5% body weight loss at 36 weeks in Phase 2 obesity trials. ([MedCity News](https://medcitynews.com/2026/10/corxel-obesity-oral-glp-1-amanat-spac-merger-weight-loss-aman/), News)
2. Corxel Pharmaceuticals is developing oral drug candidates, with lead product CX11 targeting obesity, type 2 diabetes and cardiometabolic conditions. ([Investing.com](https://www.investing.com/news/stock-market-news/obesity-drug-developer-corxel-to-go-public-in-us-via-spac-deal-4973283), News)

## Provenance

Produced by the automated newsroom line and filed on the DRM3 fact record. Content hash sha256:b5bf86ee44358a24a419131fe87f7acc1c1bab5085cd9661310699ab98056be0. Signed receipt 9KDs8t_EHGNAD6M1rOB1... (Ed25519).
Machine-readable proof: https://dietetics.news/story/ed97a7dc7c9040a2a3074f18784a0b5a/proof
HTML edition: https://dietetics.news/story/ed97a7dc7c9040a2a3074f18784a0b5a

A signature proves who filed this and that it has not changed since. It never makes a claim true.